IMPLANET: Successful First Surgical Procedures with New Jazz Lock® Implant

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:
IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext: IMPL, FR0010458729,
PEA-PME eligible), a medical technology company specializing in
vertebral and knee-surgery implants, today announces the successful
results of the first surgical procedures using the Jazz Lock®.
Having obtained CE marking and 510K clearance, Jazz Lock has been used
in select hospitals in France, Italy and the United States. Initial
positive results in over 25 cases strengthen Implanet’s intention to
carry out the wide-scale international launch of Jazz Lock by the end of
the year.
The first component of an innovative range of band products designed for
degenerative spine disorder surgery, Jazz Lock broadens the Jazz
technological platform, allowing Implanet to expand its activity in a
spine market estimated to be worth over $200 million worldwide¹.
Implanet offers surgeons a new implant with an optimized and
reproducible surgical technique. Based on the polyester band platform,
Jazz Lock simplifies the surgical procedure by replacing the locking
screw and connecting rod with an innovative locking system.
Doctor Vincent Cunin, Deputy Chief of Service in the Spine Surgery
department at Hospices Civils de Lyon (HCL), says: “As a spine
surgeon, I have been using band implants for the last four years to
correct spine deformities, with excellent post-operative clinical
results. Jazz Lock’s arrival as part of the Implanet band range is a
major breakthrough. This new implant’s ease of use during the first
surgical procedures in Lyon, as well as the very encouraging initial
post-operative clinical results, validate our choice. We will now follow
these patients to confirm the long term results. In my opinion, Jazz
Lock will quickly become an indispensable spine implant to surgeons
across the globe.”
Ludovic Lastennet, CEO of Implanet, adds: “As announced following the
regulatory clearance, Jazz Lock® is the first component of an innovative
range of band products designed for degenerative spine disorders that
will rapidly be launched in accordance with our business plan. The
positive results obtained in the first surgical procedures illustrate
this implant’s potential for patients and surgeons alike. Jazz Lock®
further expands the breadth of our product offering, with its launch is
scheduled for upcoming major spine congresses: Eurospine in Berlin in
early October and NASS in Boston (USA) in late October.”
Next financial press release: results for the 1^st half
of 2016, on September 22, 2016, after market.
Upcoming congresses and conferences:

• SRS in Prague, September 21 to 24, 2016
• ICCC in São Paulo, September 30 to October 1, 2016
• EUROSPINE in Berlin, October 6 to 8, 2016
• NASS in Boston, October 26 to 28, 2016
• SOFCOT in Paris, November 8 to 11, 2016

Reminder of recent press releases:

• Green light for a new implant: Jazz Lock®, April 2016
• Q1 2016 revenues: Strong increase in U.S. JAZZ sales: +106%, April 2016
• Launch of the new Jazz Claw® implant, May 2016
• Q2 2016 record revenue of €2.1 million with Spine sales growing by
  +68%, July 2016

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that
manufactures high-quality implants for orthopedic surgery. Its flagship
product, the JAZZ latest-generation implant, aims to treat spinal
pathologies requiring vertebral fusion surgery. Protected by four
families of international patents, JAZZ has obtained 510(k) regulatory
clearance from the Food and Drug Administration (FDA) in the United
States and the CE mark. IMPLANET employs 48 staff and recorded 2015
sales of €6.7 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in
Boston in 2013.
IMPLANET is listed on Compartment C of the
Euronext™ regulated market in Paris.
¹ Source: i-Data for 2010